RxDoctor Payments Data

Xiaochuan Chen, MD

Internal Medicine · Hayward, CANPI 1750549614

Payments from drug & device makers

$1,139in general payments, 2019–2025

Across 21 payments — averaging $54.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$225
  • Kowa Pharmaceuticals America, Inc.$137
  • Vertos Medical, Inc.$132
  • Boehringer Ingelheim$124
  • AstraZeneca$120
  • Phathom Pharmaceuticals, Inc.$110
  • plus $291 from 6 others

What the payments were for

  • Food & beverage$1,139100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,139 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$62,204
Medicare patients
101
Services billed
524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin41$53,240
JanuviaSitagliptin Phosphate18$28,689
FarxigaDapagliflozin Propanediol29$24,534
VemlidyTenofovir Alafenamide13$21,750
RybelsusSemaglutide11$14,858
EntrestoSacubitril/Valsartan17$12,501
TrulicityDulaglutide13$12,099
Atorvastatin Calcium445$4,602
Icosapent Ethyl13$4,291
Amlodipine Besylate346$2,762
Ezetimibe22$2,622
Valsartan117$2,469
Rosuvastatin Calcium87$2,432
Losartan Potassium192$1,993
Alendronate Sodium200$1,982

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$124$53,24041 claims
AstraZenecaFarxiga$120$24,53429 claims
Novo NordiskRybelsus$61$14,85811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Hayward

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →